drugset / Trial / NCT06672666

Use of CBD in the Treatment of Anxiety

NCT06672666 ↗

Phase 2 Active not recruiting 30 enrolled University of Florida
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will examine the doses, safety, and test the preliminary efficacy of hemp-derived CBD product for improving anxiety symptoms and sleep disturbances among individuals with anxiety. A 4-week, randomized, double-blind, placebo-controlled trial will be conducted to determine the safety, tolerability, preliminary efficacy, and acceptability of 50 to 150 mg/day of CBD. The treatment period will consist of a two-week titration period followed by a 2- week maintenance period. In addition, the study seeks to examine whether changes in sleep disturbances precede changes in anxiety symptoms.

Timeline

Start
2025-01-06
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 150 mg —